ConvaTec Group (CTEC.L) Stock Price
ConvaTec Group Price
Over the last 12 years ConvaTec Group grew revenue by 3.2% annually, reaching 2.49 B USD. Earnings per share have grown at 0.9% per year over the last 8 years. For ConvaTec Group, the net margin of 7.2% is up versus 5.8% a few years ago. At today's price the dividend yield works out to roughly 1.55%. The payout ratio is around 76% of earnings. The dividend has grown at 21.5% per year over the past 8 years.
ConvaTec Group stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
ConvaTec Group business model & stock analysis
Frequently asked questions about ConvaTec Group
The business model of ConvaTec Group PLC revolves around providing innovative medical products and services. ConvaTec is a global medical technology company that specializes in the development, manufacturing, and distribution of products for the care of chronic conditions. Their diverse product portfolio includes advanced wound care, ostomy care, continence, and critical care products. By focusing on research, development, and collaboration with healthcare professionals, ConvaTec aims to improve the quality of life for patients worldwide. With a commitment to continuous innovation and a customer-centric approach, ConvaTec Group PLC strives to meet the evolving needs of the healthcare industry.
ConvaTec Group PLC is primarily active in the healthcare industry.
The main competitors of ConvaTec Group PLC in the market are Coloplast A/S, Medtronic plc, and Hollister Incorporated.
ConvaTec Group PLC is a well-established global medical products and technologies company. Founded in 1978, it has a rich and extensive history in the healthcare industry. ConvaTec specializes in developing and manufacturing innovative medical devices, including advanced wound care, ostomy care, continence and critical care products. With headquarters in the UK, ConvaTec operates in over 100 countries, serving healthcare professionals and patients worldwide. Over the years, ConvaTec has earned a strong reputation for its high-quality products, commitment to research and development, and dedication to improving patient lives. As a leading player in the medical industry, ConvaTec Group PLC continues to strive for excellence and innovation in healthcare solutions.
ConvaTec Group PLC has achieved several significant milestones throughout its history. Some notable achievements include the company's initial public offering (IPO) in 2016, which marked a major milestone in its growth and development. Additionally, ConvaTec has successfully introduced innovative products and solutions in the healthcare industry, such as its advanced wound care products, ostomy care solutions, and continence and critical care products. The company has also expanded its global footprint by establishing a strong presence in various geographical markets, providing healthcare solutions to a wide range of patients worldwide. ConvaTec's commitment to continuous innovation, product development, and global expansion has contributed to its success and reputation in the healthcare industry.
ConvaTec Group PLC is primarily present in various countries and regions worldwide. As a global company, its operations span across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region. With a strong international presence, ConvaTec serves customers and patients in numerous countries, including the United States, Canada, United Kingdom, Germany, France, Italy, Spain, Australia, China, Japan, and many more. By establishing a diverse and extensive geographic footprint, ConvaTec aims to provide its innovative healthcare products and solutions to a broad range of individuals, healthcare professionals, and healthcare systems around the world.
ConvaTec Group PLC represents a strong set of values and a customer-centric corporate philosophy. With a focus on improving the lives of patients, ConvaTec is committed to delivering innovative medical products and solutions. They aim to provide high-quality, reliable, and advanced healthcare technologies that meet the diverse and evolving needs of individuals. By leveraging their expertise and collaborative approach, ConvaTec aims to drive positive healthcare outcomes and enhance patient experiences. With a global presence and a dedicated team, they continuously strive to make a difference in the healthcare industry, emphasizing integrity, innovation, and compassion.
21 analysts currently rate the ConvaTec Group stock: 19 recommend buying, 2 holding and 0 selling. For 2026, analysts expect ConvaTec Group to generate revenue of 2.54 B USD and earnings per share of 0.20 USD.
Converted at the current exchange rate, the ConvaTec Group share trades at 2.91 EUR (3.25 USD).
The ConvaTec Group share (CTEC.L) is listed on 7 stock exchanges, including: London (CTEC.L), SIX (Zürich) (2CV.SW), Frankfurt (2CV.F), München (2CV.MU), Düsseldorf (2CV.DU).
The ConvaTec Group PLC is a British company specializing in medical products and services. It offers a wide range of products in four business areas: ostomy products, continence and intimate hygiene products, wound therapeutics, and infusion and respiratory products. Ostomy Products ConvaTec offers a comprehensive range of ostomy products for people with intestinal diseases such as colon cancer, Crohn's disease, or ulcerative colitis. The products are developed in close collaboration with patients and healthcare professionals to ensure the best fit and user-friendliness. Continence and Intimate Hygiene Products ConvaTec also produces products for continence and intimate hygiene, such as diapers, pads, and skincare products. These products are designed for patients with urinary or fecal incontinence, as well as for people with limited mobility. Wound Therapeutics The wound therapeutics business area includes a wide range of products for wound care, including compression bandages, foam and hydrocolloid dressings, alginates, and silicone gels. These products are used to treat wounds such as pressure ulcers, venous leg ulcers, and surgical wounds. Infusion and Respiratory Products The infusion and respiratory products business area offers a wide range of medical products used in the treatment of lung diseases such as COPD, asthma, and pneumonia. These products include inhalers, oxygen therapy devices, and infusion devices. Additional Services ConvaTec also provides services such as training for healthcare professionals and patients. These trainings cover various areas, including stoma care, wound care, and continence management. Additionally, the company offers consulting services for healthcare professionals. Business Model ConvaTec achieves its business model by identifying needs and challenges in the healthcare industry and developing and manufacturing innovative products and services. The company works closely with healthcare professionals and patients to ensure that the products meet the users' requirements and needs. The company also focuses on a strong presence in the global market, facilitated by strategic acquisitions and partnerships. ConvaTec has offices and distribution centers in over 100 countries worldwide and employs over 9,000 people. Furthermore, ConvaTec places great emphasis on research and development and invests in the development of new products and technologies. The company collaborates closely with universities and research institutions to support its research and development activities. Overall, ConvaTec's business model is focused on developing and globally distributing innovative products and services to meet the needs of healthcare professionals and patients, thereby improving the health and well-being of millions of people.
The expected revenue of ConvaTec Group is 2.54 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of ConvaTec Group is 408.20 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of ConvaTec Group is currently 16.01. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ConvaTec Group stock.
The price-to-sales ratio (P/S) of ConvaTec Group is currently 2.57. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ConvaTec Group stock.
The Eulerpool Quality Score for ConvaTec Group is 5/10.
The ISIN of ConvaTec Group is GB00BD3VFW73. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of ConvaTec Group is A2AUD3. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of ConvaTec Group is CTEC.L. The ticker symbol is used to trade ConvaTec Group shares on the stock exchange.
ConvaTec Group stock
ConvaTec Group Peer Group
ConvaTec Group Ticker
ConvaTec Group FIGI
All fundamentals and in-depth analysis of ConvaTec Group
Our stock analysis for ConvaTec Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ConvaTec Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.